NEW YORK, Sept 29 - SEQUENOM (Nasdaq: SQNM) said Friday it had sold four of its MassArray systems for SNP analysis, bringing the company’s installed commercial base of systems to 16.

Sequenom sold the systems to Hitachi (NYSE: HIT), Genetics Institute, Genaissance Pharmaceuticals (Nasdaq: GNSC) and Integrated DNA Technologies. It did not disclose the terms of the deals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.